Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial

HIV Infections Clinical Trial

— ARTIST  

Official title:

AntiRetroviral Therapy In Second-line: Investigating Tenofovir-lamivudine-dolutegravir (ARTIST): a Randomised Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03991013
• Other study ID #: ARTIST
• Status: Completed
• Phase: Phase 2
• Start date: August 8, 2019
• Est. completion date: October 27, 2022

Study information

• Verified date: November 2022
• Source: University of Cape Town
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The strategy to support virological suppression on second-line antiretroviral treatment (ART) includes the provision of ART that has a low pill burden, good tolerability, low toxicity, is easily monitored, has a high barrier to resistance, and that is low cost. The fixed-dose combination of tenofovir-lamivudine-dolutegravir offers significant advantage as a potential second-line regimen compared to the World Health Organization standard of care second-line regimen of zidovudine-lamivudine-dolutegravir, in terms of cost, tolerability and monitoring requirements.

The ARTIST study is a phase 2, randomised, double-blind, placebo-controlled trial aiming to determine the proportion of patients achieving virological suppression when recycling the tenofovir-emtricitabine/lamivudine backbone with dolutegravir (tenofovir-lamivudine-dolutegravir fixed-dose combination) as a second-line with and without a lead-in supplementary dose of dolutegravir, in patients failing a tenofovir-emtricitabine/lamivudine-efavirenz first-line regimen.

There is evidence to suggest that even in the presence of resistance mutations to tenofovir and lamivudine (K65R or M184V/I), using this backbone with dolutegravir will provide an effective second-line regimen in patients who have failed a first-line regimen of tenofovir-emtricitabine/lamivudine-efavirenz. The strategy of giving a lead-in supplementary dose of dolutegravir is in view of the inducing effect of efavirenz on dolutegravir metabolism and transport that persists for 2 weeks after efavirenz is stopped; the inducing effect decreases with time after efavirenz is stopped.

Given that these patients will have elevated viral loads, a high baseline risk of nucleoside reverse transcriptase inhibitor (NRTI) resistance and efavirenz resistance, and the inducing effect of efavirenz on dolutegravir metabolism and transport that persists for 2 weeks, this study will comprise two stages. The first stage will evaluate virological suppression in 62 participants initiated on the fixed-dose combination of tenofovir-lamivudine-dolutegravir with a lead-in supplementary dose of dolutegravir for the first 14 days. The study will progress to the second stage if this strategy proves effective, and 130 participants will then be randomised to receive the fixed-dose combination of tenofovir-lamivudine-dolutegravir with and without this lead-in dose.

The primary endpoint is virological suppression (viral load <50 copies/mL) at 24 weeks.

A pharmacokinetic sub-study will be conducted on 12 participants in stage 1 and 24 participants in stage 2, to assess the trough concentrations of dolutegravir and off-treatment concentrations of efavirenz at day 3, 7, 14, and 28. This is to evaluate the need for the lead-in supplementary dose of dolutegravir.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 192
• Est. completion date: October 27, 2022
• Est. primary completion date: April 26, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

HIV positive patients over 18 years old, who have failed first-line ART regimen of tenofovir-emtricitabine/lamivudine-efavirenz, are able to attend the study clinic for one year of scheduled visits and who have given written, informed consent will be enrolled in this study. In female patients of child-bearing potential, those willing to use effective and reliable contraception for the duration of the study will be eligible.

Failure of a first-line regimen is defined as a viral load (VL) of >1000 copies/mL (within the previous two months) and an immediately prior VL >1000 copies/mL, taken 2-24 months prior (based on data captured by National Health Laboratory Service).

Exclusion Criteria:

• If the patient has two VLs 2-3 months apart: >2 log drop in VLs between the most recent VL (within the previous two months) and the immediately prior VL (taken 2-3 months prior)

• CD4 count <100 cells/microlitre

• Estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula

• Alanine aminotransferase >100 U/L or total bilirubin >twice the upper limit of normal

• Pregnant or desire to become pregnant during the study period (48 weeks)

• Breastfeeding

• Being treated for active tuberculosis (TB) or concern that patient has undiagnosed active TB (based on symptom screening) as rifampicin reduces the concentrations of dolutegravir and thus requires dose adjustments

• Any current diagnosis of malignancy

• Allergy or intolerance to one of the drugs in regimen

• Active, severe psychiatric disease judged likely to impact adherence

• Current substance abuse judged likely to impact adherence

• On treatment for AIDS-defining condition (not including secondary prophylaxis maintenance therapy)

• Any other clinical condition that in the opinion of an investigator puts the patient at increased risk if participating in the study

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Dolutegravir 50 mg
Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
• Placebo
Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).

Locations

Country	Name	City	State
South Africa	Khayelitsha Site B/Ubuntu Community Health Clinic	Cape Town	Western Cape

Sponsors (3)

Lead Sponsor	Collaborator
University of Cape Town	Médecins Sans Frontières, Belgium, Wellcome Trust

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Virological suppression at 24 weeks	Proportion of participants with HIV viral load <50 copies/mL at 24 weeks analysed by modified intention to treat (ITT) and according to the FDA snapshot algorithm, overall and stratified by the presence or absence of resistance to tenofovir and lamivudine at baseline.	24 weeks
Secondary	Antiretroviral resistance mutations by genotypic resistance testing	To describe resistance profile at baseline (NRTI and efavirenz resistance), and treatment-emergent resistance to integrase inhibitor and NRTI in participants who experience virological failure.	Baseline, 24 and 48 weeks
Secondary	Residual efavirenz concentrations and dolutegravir trough concentrations	To evaluate the trough concentrations (ng/mL) of dolutegravir and the residual concentrations (ng/mL) of efavirenz in the period after switching regimens. To evaluate the proportion of participants with dolutegravir trough concentrations above the protein-adjusted 90% inhibitory concentration (PA-IC90) value at all pharmacokinetics time points.	First 28 days
Secondary	Virological suppression at 12 and 48 weeks (modified ITT)	Proportion of participants with HIV viral load <50 copies/mL at 12 and 48 weeks analysed by modified ITT.	12 and 48 weeks
Secondary	Virological suppression at 12, 24 and 48 weeks (per protocol)	Proportion of participants with HIV viral load <50 copies/mL at 12, 24 and 48 weeks analysed per protocol.	12, 24 and 48 weeks
Secondary	Adherence to treatment	To describe tenofovir-diphosphate concentration (ng/mL) in participants who experience virological failure and matched controls from among those who are suppressed at 24 and 48 weeks.	24 and 48 weeks
Secondary	CD4 change at 24 and 48 weeks	Change in CD4 count from screening at week 24 and 48.	24 and 48 weeks
Secondary	Adverse events	To describe grade 3 and 4 drug-related adverse events, serious adverse events, and any adverse event requiring discontinuation of any drug in the ART regimen.	48 weeks
Secondary	All-cause mortality	To describe all-cause mortality.	48 weeks